United Therapeutics navigates competition with solid Q1 results, revenue growth projections, and a solid balance sheet. Learn ...

Insmed (NASDAQ:INSM) announced Tuesday that TPIP, its experimental therapy for pulmonary arterial hypertension, succeeded in ...

United Therapeutics Corporation stock was down substantially yesterday as rival Insmed's PAH data blew the market away. Click ...

United Therapeutics UTHR shares soared 3.5% in the last trading session to close at $286.14. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for. United Therapeutics met analysts’ revenue expectations last ...

Leerink analyst Roanna Ruiz lowered the firm’s price target on United Therapeutics (UTHR) to $420 from $430 and keeps an Outperform rating on the shares.United Therapeutics’ Q4 earnings ...

Morningstar brands and products Company Portfolio ...

United Therapeutics (NASDAQ:UTHR) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world’s first successful transplant of a UThymoKidney™, which the company produced ...

You can reach Jason on Signal at JasonMast.05. United Therapeutics said Monday that the Food and Drug Administration has cleared it to begin the first clinical trial testing whether organs from ...